Anita Figueras
Anita Figueras has been a lung cancer patient since 2014, when she was diagnosed with stage IV adenocarcinoma. She has an EGFR mutation, and has developed the T790M resistance mutation. Anita is on her third line of treatment. She participated in the Clovis Pharmaceuticals’ phase II trial for CO-1686, and spoke to the FDA’s Oncologic Drug Advisory Committee about her experience on the experimental drug. She was diagnosed with MS 20 years ago, and has long experience with living with a chronic illness.
Read more
Has your oncologist talked to you about your dental health, beyond asking if you have mouth sores? Oncologists are busy …
After four chemotherapy infusions, I was feeling pretty good. My energy level and feeling of well-being were on the rise. …
According to the National Cancer Institute, 38.5% of men and women will develop cancer of some kind during their lives.1 …
Are you looking for a website where you can find the latest news about lung cancer research and treatment? Would …
Read Part 1 of Anita and Karen’s discussion here. You are active online, notably with your “Trekking Through Cancerland” Facebook …
In a recent conversation with lung cancer patient and advocate Karen Loss, she remarked that there was little discussion on …
The American Lung Association (ALA) has long sent staff and volunteers to Congressional offices to advocate for actions that improve …
